ANCC FNP Review Questions with answers correct
1. special considerations for Thiazides: Chlorthalidone is preferred on the basis of
prolonged half-life and proven trial reduction of CVD.
,Monitor for hyponatremia and hypokalemia, monitor uric acid and calcium levels.
Use with caution in patients with history of acute gout unless patient is on uric acid-lowering therapy.
2. special considerations for ACE inhibitors: Do not use in combination with ARBs or
direct renin inhibitor.
There is an increased risk of hyperkalemia, especially in patients with CKD or in those on K+ supplements
or K+-sparing drugs.
There is a risk of acute renal failure in patients with severe bilateral renal artery
stenosis. Do not use if patient has history of angioedema with ACE inhibitors.
ACE inhibitor cough is common, in 5 to 20 percent of patients, due to bradykinin production.
,Avoid in pregnant females or females of reproductive age without adequate contraception
3. special considerations for Angiotensin receptor blockers: Do not use
in combination with ACE inhibitors or direct renin inhibitor.
There is an increased risk of hyperkalemia in CKD or in those on K+ supplements or K+-
sparing drugs. There is a risk of acute renal failure in patients with severe bilateral renal artery
stenosis.
Do not use if patient has history of angioedema with ARBs. Patients with a history of angioedema with an
ACE inhibitor can receive an ARB beginning 6 weeks after ACE inhibitor is discontinued.
Avoid in pregnant females or females of reproductive age without adequate contraception.
, Lower risk of cough than ACE-Is.
4. special considerations for Calcium channel blockers: Associated with dose-
related pedal edema, which is more common in females than men.
1. special considerations for Thiazides: Chlorthalidone is preferred on the basis of
prolonged half-life and proven trial reduction of CVD.
,Monitor for hyponatremia and hypokalemia, monitor uric acid and calcium levels.
Use with caution in patients with history of acute gout unless patient is on uric acid-lowering therapy.
2. special considerations for ACE inhibitors: Do not use in combination with ARBs or
direct renin inhibitor.
There is an increased risk of hyperkalemia, especially in patients with CKD or in those on K+ supplements
or K+-sparing drugs.
There is a risk of acute renal failure in patients with severe bilateral renal artery
stenosis. Do not use if patient has history of angioedema with ACE inhibitors.
ACE inhibitor cough is common, in 5 to 20 percent of patients, due to bradykinin production.
,Avoid in pregnant females or females of reproductive age without adequate contraception
3. special considerations for Angiotensin receptor blockers: Do not use
in combination with ACE inhibitors or direct renin inhibitor.
There is an increased risk of hyperkalemia in CKD or in those on K+ supplements or K+-
sparing drugs. There is a risk of acute renal failure in patients with severe bilateral renal artery
stenosis.
Do not use if patient has history of angioedema with ARBs. Patients with a history of angioedema with an
ACE inhibitor can receive an ARB beginning 6 weeks after ACE inhibitor is discontinued.
Avoid in pregnant females or females of reproductive age without adequate contraception.
, Lower risk of cough than ACE-Is.
4. special considerations for Calcium channel blockers: Associated with dose-
related pedal edema, which is more common in females than men.
